$100 million NuvaRing settlement finalized

A $100 million settlement involving NuvaRing, a birth-control device linked to sometimes-fatal side effects, will stand now that enough claimants have chosen to opt into the agreement.

U.S. District Judge Rodney W. Sippel of St. Louis approved the in February, but NuvaRing maker Merck & Co. had the right to abandon the deal if less than 95 percent of claimants opted in.

Attorneys for the claimants and Merck said Thursday that the 95 percent threshold has been reached. St. Louis attorney Roger Denton, lead lawyer for those who sued, says about 3,800 claimants will share in the settlement.

The lawsuits allege faulty design and testing, and claim that potential hazards of the device were not adequately disclosed.

Merck says there is "substantial" evidence to show that NuvaRing is safe.

Related Stories

Germany's Merck to buy materials supplier AZ

date Dec 05, 2013

Germany's Merck KGaA has announced plans to buy AZ Electronic Materials, which supplies high-tech materials for the electronics industry, for about 1.6 billion pounds ($2.6 billion).

Recommended for you

Cardinal Health paying $26.8 million in FTC settlement

date 12 hours ago

Cardinal Health will pay $26.8 million as part of a settlement with the Federal Trade Commission over charges it monopolized the sale in 25 markets of diagnostic drugs known as low-energy radiopharmaceuticals.

Selecting the right tool for the job

date Apr 14, 2015

Randomized clinical trials of new drugs have long been considered the "gold standard" in determining safety and efficacy before drugs, biologics, vaccines or devices are introduced to the general public. However, in the case ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.